Cargando…
miR-223-3p Inhibits Human Osteosarcoma Metastasis and Progression by Directly Targeting CDH6
Cadherin-6 (CDH6) is aberrantly expressed in cancer and closely associated with tumor progression. However, the functions of CDH6 in human osteosarcoma and the molecular mechanisms underlying CDH6 in osteosarcoma oncogenesis remain poorly understood. In this work, we assessed the role of CDH6 in hum...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993963/ https://www.ncbi.nlm.nih.gov/pubmed/29628305 http://dx.doi.org/10.1016/j.ymthe.2018.03.009 |
_version_ | 1783330323886505984 |
---|---|
author | Ji, Quanbo Xu, Xiaojie Song, Qi Xu, Yameng Tai, Yanhong Goodman, Stuart B. Bi, Wenzhi Xu, Meng Jiao, Shunchang Maloney, William J. Wang, Yan |
author_facet | Ji, Quanbo Xu, Xiaojie Song, Qi Xu, Yameng Tai, Yanhong Goodman, Stuart B. Bi, Wenzhi Xu, Meng Jiao, Shunchang Maloney, William J. Wang, Yan |
author_sort | Ji, Quanbo |
collection | PubMed |
description | Cadherin-6 (CDH6) is aberrantly expressed in cancer and closely associated with tumor progression. However, the functions of CDH6 in human osteosarcoma and the molecular mechanisms underlying CDH6 in osteosarcoma oncogenesis remain poorly understood. In this work, we assessed the role of CDH6 in human osteosarcoma and identified that the expression of CDH6 was closely related with the overall survival and poor prognosis of osteosarcoma patients. MicroRNAs (miRNAs) have been implicated as important epigenetic regulators during the progression of osteosarcoma. Using dual-luciferase reporter assays, we showed that miR-223-3p suppresses CDH6 expression by directly binding to the 3′ UTR of CDH6. miR-223-3p overexpression significantly inhibited cell invasion, migration, growth, and proliferation by suppressing the CDH6 expression in vivo and in vitro. Besides, CDH6 overexpression in the miR-223-3p-transfected osteosarcoma cells effectively rescued the inhibition of cell invasion, migration, growth, and proliferation mediated by miR-223-3p. Additionally, Kaplan-Meier analysis suggests that the expression of miR-223-3p predicts favorable clinical outcomes for osteosarcoma patients. Moreover, the expression of miR-223-3p was downregulated in osteosarcoma patients and was negatively associated with the expression of CDH6. Collectively, these data highlight that miR-223-3p/CDH6 axis is an important novel pleiotropic regulator and could early predict the metastatic potential in human osteosarcoma treatments. |
format | Online Article Text |
id | pubmed-5993963 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | American Society of Gene & Cell Therapy |
record_format | MEDLINE/PubMed |
spelling | pubmed-59939632019-05-02 miR-223-3p Inhibits Human Osteosarcoma Metastasis and Progression by Directly Targeting CDH6 Ji, Quanbo Xu, Xiaojie Song, Qi Xu, Yameng Tai, Yanhong Goodman, Stuart B. Bi, Wenzhi Xu, Meng Jiao, Shunchang Maloney, William J. Wang, Yan Mol Ther Original Article Cadherin-6 (CDH6) is aberrantly expressed in cancer and closely associated with tumor progression. However, the functions of CDH6 in human osteosarcoma and the molecular mechanisms underlying CDH6 in osteosarcoma oncogenesis remain poorly understood. In this work, we assessed the role of CDH6 in human osteosarcoma and identified that the expression of CDH6 was closely related with the overall survival and poor prognosis of osteosarcoma patients. MicroRNAs (miRNAs) have been implicated as important epigenetic regulators during the progression of osteosarcoma. Using dual-luciferase reporter assays, we showed that miR-223-3p suppresses CDH6 expression by directly binding to the 3′ UTR of CDH6. miR-223-3p overexpression significantly inhibited cell invasion, migration, growth, and proliferation by suppressing the CDH6 expression in vivo and in vitro. Besides, CDH6 overexpression in the miR-223-3p-transfected osteosarcoma cells effectively rescued the inhibition of cell invasion, migration, growth, and proliferation mediated by miR-223-3p. Additionally, Kaplan-Meier analysis suggests that the expression of miR-223-3p predicts favorable clinical outcomes for osteosarcoma patients. Moreover, the expression of miR-223-3p was downregulated in osteosarcoma patients and was negatively associated with the expression of CDH6. Collectively, these data highlight that miR-223-3p/CDH6 axis is an important novel pleiotropic regulator and could early predict the metastatic potential in human osteosarcoma treatments. American Society of Gene & Cell Therapy 2018-05-02 2018-03-14 /pmc/articles/PMC5993963/ /pubmed/29628305 http://dx.doi.org/10.1016/j.ymthe.2018.03.009 Text en © 2018 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Ji, Quanbo Xu, Xiaojie Song, Qi Xu, Yameng Tai, Yanhong Goodman, Stuart B. Bi, Wenzhi Xu, Meng Jiao, Shunchang Maloney, William J. Wang, Yan miR-223-3p Inhibits Human Osteosarcoma Metastasis and Progression by Directly Targeting CDH6 |
title | miR-223-3p Inhibits Human Osteosarcoma Metastasis and Progression by Directly Targeting CDH6 |
title_full | miR-223-3p Inhibits Human Osteosarcoma Metastasis and Progression by Directly Targeting CDH6 |
title_fullStr | miR-223-3p Inhibits Human Osteosarcoma Metastasis and Progression by Directly Targeting CDH6 |
title_full_unstemmed | miR-223-3p Inhibits Human Osteosarcoma Metastasis and Progression by Directly Targeting CDH6 |
title_short | miR-223-3p Inhibits Human Osteosarcoma Metastasis and Progression by Directly Targeting CDH6 |
title_sort | mir-223-3p inhibits human osteosarcoma metastasis and progression by directly targeting cdh6 |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993963/ https://www.ncbi.nlm.nih.gov/pubmed/29628305 http://dx.doi.org/10.1016/j.ymthe.2018.03.009 |
work_keys_str_mv | AT jiquanbo mir2233pinhibitshumanosteosarcomametastasisandprogressionbydirectlytargetingcdh6 AT xuxiaojie mir2233pinhibitshumanosteosarcomametastasisandprogressionbydirectlytargetingcdh6 AT songqi mir2233pinhibitshumanosteosarcomametastasisandprogressionbydirectlytargetingcdh6 AT xuyameng mir2233pinhibitshumanosteosarcomametastasisandprogressionbydirectlytargetingcdh6 AT taiyanhong mir2233pinhibitshumanosteosarcomametastasisandprogressionbydirectlytargetingcdh6 AT goodmanstuartb mir2233pinhibitshumanosteosarcomametastasisandprogressionbydirectlytargetingcdh6 AT biwenzhi mir2233pinhibitshumanosteosarcomametastasisandprogressionbydirectlytargetingcdh6 AT xumeng mir2233pinhibitshumanosteosarcomametastasisandprogressionbydirectlytargetingcdh6 AT jiaoshunchang mir2233pinhibitshumanosteosarcomametastasisandprogressionbydirectlytargetingcdh6 AT maloneywilliamj mir2233pinhibitshumanosteosarcomametastasisandprogressionbydirectlytargetingcdh6 AT wangyan mir2233pinhibitshumanosteosarcomametastasisandprogressionbydirectlytargetingcdh6 |